• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Steven Goetz Joins Motif Neurotech as Chief Technology Officer

    ZAP Surgical Wins Two More IP Battles with Elekta

    3D Systems Partners with Klarity to Expand Distribution of VSP Bolus Solution

    Zeus Introduces Absorv XSE Oriented Tubing

    Laminate's VasQ Nabs De Novo Nod to Create AVFs for Dialysis Access
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    MPO's 2023 Medtech Supply Chain Survey

    Exceeding Medical Device Extrusion Expectations

    Medical Device Micromolders Discuss the 'Minor Details'

    Superior Subtractive Solutions for Machining Medtech

    Assembly & Automation Experts Share Thoughts on Medtech Trends
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Back to School for Medical Device Cybersecurity Training

    Driving Clinical Trial Excellence to Help Study Teams Run a Faster Relay Race

    Medtech’s Supply Chain: From Disruption to Opportunity

    Are Medtech’s Mega-Deals Gone For Good?

    Will a Skilling Gap Hinder Organizational Readiness for Medtech’s New Age of AI?
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Medbio LLC

    Providence Enterprise USA Inc.

    Cirtec Medical

    Johari Digital Healthcare Ltd.

    LEMO USA Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Wearables Are Changing the Way We Collect Real-World Data in Clinical Trials

    Could Medtech Ever Stop a Hospital Killer in Their Tracks?

    A One-Stop-Shop, Turnkey Solution Is Paramount for Success

    How Additive and Subtractive Manufacturing Are Revolutionizing the Medical Device Industry

    Medical Device Commercialization: It’s What, Not When, to Transfer to Manufacturing
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Medbio LLC

    Providence Enterprise USA Inc.

    Cirtec Medical

    Johari Digital Healthcare Ltd.

    LEMO USA Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Prepare Now for Updated ISO 10993-17

    Latest revision will be a significant change from the 2002 version of the standard.

    Prepare Now for Updated ISO 10993-17
    Dr. Sherry Parker, Senior Director, Regulatory Toxicology, WuXi AppTec Medical Device Testing 12.15.21
    A significant increase in understanding the chemical constituents in medical devices and patient safety risks is underway. Sparked by the publication of ISO 10993-1:2018,1 this standard is intended to instill a greater focus on a risk-based approach to biological evaluations. Further changes and additions to the standards continue to support this effort, and the upcoming version of ISO 10993-172 will provide critical guidance for the evaluation of chemical constituents.
     
    Medical device manufacturers that make the necessary efforts to stay ahead of these evolving standards can increase their chances of future regulatory success. Companies should take advantage of this time before the standards are implemented to stay informed of developments and better understand the impact of the new requirements and their associated revisions.
     
    Impact of ISO 10993-18 on Toxicological Risk Assessments
    The publication of ISO 10993-18:20203 established a need for medical device manufacturers to investigate their products’ chemical constituents more rigorously. Consequently, these evaluations can produce considerably larger amounts of data than in the past. This requires toxicologists to assess the risk of each chemical identified.
     
    Companies typically use chemical characterization testing to provide a detailed understanding of the chemical constituents in medical device materials and finished products. By gathering chemical information, often through performing extractable and leachable (E/L) testing, chemists can detect chemical constituents to the level of manufacturing process residuals. Laboratories then evaluate these chemical constituents in a toxicological risk assessment (TRA). Still, results can trigger questions when unknown chemicals remain or potentially toxic substances are present. The combination of these activities helps identify any remaining device concerns before moving forward with additional testing.
     
    One notable revision to ISO 10993-18 is the introduction of the analytical evaluation threshold (AET). Using the AET, laboratories must identify and quantify all chemicals at or above the determined threshold to garner more complete chemical characterization at a level to support the TRA. As the duration of a device’s intended patient exposure increases, experts must set a lower identification and quantification threshold for chemical characterization. Furthermore, to account for the analytical uncertainty of semi-quantitative screening, it is expected that uncertainty factors are used in the AET calculation. This expectation results in reporting chemicals well below the threshold of toxicological concern.
     
    Ultimately, these lower reporting thresholds create massive data sets. Not only are toxicologists challenged by working with these massive data, but the regulatory expectation is to evaluate each chemical’s hazard and toxicological risk. Adhering to these expectations is important when trying to achieve regulatory success.
     
    Suppose testing laboratories cannot reach these low reporting thresholds due to large devices, extraction volumes, or limits of analytical sensitivity. In those cases, laboratories must concentrate the extracts to increase the sensitivity of the analysis. Concentrating extracts is not ideal, as it may produce volatile compounds losses and degradation products. What results is a longer list of extractable chemicals with questionable clinical relevance and even more work for the toxicologist.
     
    In these situations, results are likely to overestimate a realistic level of toxicological risk. Overestimating the toxicological risk of a chemical could result in unnecessary regulatory concerns. An experienced toxicologist can strike the right balance between under and overestimating toxicological risks, and provide their perspective on resolving potential regulatory concerns before implementing additional testing.
     
    Evaluating Relevant Toxicological Risks
    For biological evaluations of medical devices, identifying relevant biological risks is critical for determining subsequent testing strategies. Chemical information is now a requirement for biological evaluations according to ISO 10993-1:2018. The use of chemical characterization and understanding the contact nature, duration, and device clinical use provides the necessary information for developing biological evaluation strategies.
     
    Though many biological risks can be addressed with biocompatibility testing, there are also biological risks that can be addressed with a TRA, including systemic toxicity (acute, subacute/subchronic, and chronic), carcinogenicity, genotoxicity, and reproductive and developmental toxicity. Other biological endpoints, including local tissue effects (irritation, sensitization, and implantation), pyrogenicity, and hemocompatibility, are typically addressed with biological testing only.
     
    Experts develop a biological evaluation strategy to plan which endpoints a laboratory addresses with a TRA and which endpoints they deliver with biological testing. If toxicological risks are identified in the assessment, companies may still need to conduct biological testing to mitigate these risks. This comprehensive approach allows for a better understanding of risks and an informed test selection to address biological risks. It will also help to avoid unnecessary testing.   
     
    Exhaustive extractions for prolonged and permanent devices can result in hundreds, sometimes thousands, of chemical constituents. Gathering these data is a strenuous task for chemists, who identify and quantify each constituent above the AET – and not every chemistry lab has the capabilities to complete the hard work of identification. The process is also laborious for toxicologists who use this information to assess the toxicological risk associated with each chemical constituent and determine whether it could present a hazardous situation for the patient.
     
    Toxicologists identify clinically relevant toxicological risks based on both hazard and exposure. Chemical characterization data provides the necessary worst-case exposure estimates, while toxicology literature and in silico computational toxicology tools provide necessary hazard information. Toxicologists evaluate potential hazards by mining available toxicological data for critical adverse effects of the medical device’s chemical constituents. When toxicology data is insufficient or unavailable, in silico toxicology prediction tools are used.
     
    Experts derive tolerable intake levels from the existing information that considers sensitive patient populations and uncertainties of extrapolation to human exposure. The information reveals the variation between patients and the nature and duration of contact with extractable/leachable chemicals from the device.
    When appropriate, a threshold of toxicological concern (TTC) is applied as described in ISO/TS 21726:2019. Comparing the estimated tolerable intake or appropriate threshold of toxicological concern (TTC) with the worst-case exposure (estimated through chemical characterization), a ratio referred to as the margin of safety (MOS) is used as a tool to assess the overall toxicological risk.
     
    Toxicologists must understand the factors contributing to overall toxicological risk, including the intended clinical use, as medical devices may be intended for multiple patient populations, have different contact durations (e.g., single-use, repeated-use, limited, prolonged, or long-term), or use several devices for treatment. Toxicologists use this information to determine the worst-case scenario to assess risk.
     
    Evaluating relevant biological risks is not done solely through a TRA of medical device chemical constituents. This process must also include endpoints requiring evaluation through biological testing. The overall weight of evidence to support biological safety must combine chemical information, TRA, and biocompatibility data to complete the biological evaluation. Biological evaluations require expertise in medical devices, analytical chemistry, and toxicology. Companies may expect longer timelines with more rigorous chemical characterization and comprehensive TRAs than past experiences. But the upcoming revisions to ISO 10993-17 aim to facilitate TRA conduct.
     
    To better inform overall acceptance of toxicological risks, toxicologists must balance worst-case assumptions and conservative toxicological thresholds with realistic patient risk of exposure to medical device chemical constituents. Awareness is critical to avoid the repercussions of over and underestimating risk.
     
    Overestimating risk can result in unnecessary biocompatibility testing and can needlessly prevent a beneficial device from reaching the market. Conversely, underestimating risk is worse as it could result in safety concerns. Regulatory affairs professionals with an eye on ISO 10993 should utilize their knowledge to carefully select their laboratory testing partners to support the biological evaluation of their medical devices.
     
    The result of insufficiently assessing potential patient safety risks during the early product development phases could limit a company’s available opportunities to address them. These limited options could negatively impact medical device development timelines and outcomes or result in necessary risk control measures.
     
    Upcoming Revisions to ISO 10993-17
    The latest revision to ISO 10993 will be a significant change from the 2002 version of ISO 10993-17. The working group for ISO 10993-17 is working to develop and push forward the standard’s latest draft and many experts are already considering how it could improve their assessments.
     
    Those closely following the standard’s progression anticipate it will provide new tools for conducting toxicological risk assessments. The goal for the updates to ISO 10993-17 is to provide a more consistent approach to evaluating chemical constituents, benefitting both the user and the regulator. However, companies should realize that expert judgment cannot be replaced and remains pivotal to a successful assessment.
     
    Key concepts introduced in the latest ISO 10993-17 draft document include the toxicological screening limit (TSL), margin of safety (MOS) evaluation, and exposure dose estimation. Regulatory affairs professionals with a foundational understanding of these components within the standard revisions can better identify gaps in their submissions and select qualified testing partners.
     
    Toxicological Screening Limit (TSL)—The toxicologist's job is to evaluate all reported chemicals identified and quantified above the AET. This responsibility includes performing hazard identification and deriving tolerable intake levels. In addition to the very low reporting thresholds, the exaggerated and exhaustive extraction recommendations in ISO 10993-18 have increased the number of extractable chemicals that must be evaluated. This has led to extensive TRAs and time spent evaluating chemicals present at very low levels.  
     
    Intended to minimize the burden of the TRA process, the TSL is an option that reduces the number of chemical constituents the toxicologist is required to review. It does so by screening out chemicals without appreciable toxicological risk. There is a short-term (up to 30 days) and a long-term (>30 days) TSL presented in mg/device that toxicologists can apply to the total quantity of a chemical constituent.
     
    The TSL could offer significant relief to toxicologists and help expedite turnaround times when possible. Overall, it has the potential to reduce the burden of performing a full TRA.
     
    Estimation of Exposure Dose—The exposure dose is the worst-case exposure daily, and experts calculate it from chemical characterization data. Release kinetics of chemicals from a final finished medical device are an important factor they should also consider to determine worst-case daily exposure. Most chemicals are likely to be released at higher levels initially and taper off over time. This curve could result in more short-term toxicological risks, even for long-term devices.
     
    The ISO 10993-17 draft provides guidance on calculating exposure doses of chemicals based on either known or assumed release kinetics. This step allows the toxicologist to understand whether toxicological risks are short- or long-term, and help inform the toxicologist when additional release kinetics information may be needed for a chemical.
     
    Evaluating the MOS—The tolerable intake or TTC ratio of the estimated exposure dose is known as the margin of safety (MOS). The MOS is a tool that assists the toxicologist in evaluating whether the toxicological risk will be acceptable or more information is needed to assess the risk. That could include refining maximum exposure estimates, using biological testing, or applying risk control.

    Generally, a MOS greater than one supports acceptable toxicological risk, but that is not the end of the evaluation. Other elements are important for the expert to determine if the risk is acceptable. For example, a chemical constituent’s potency and severity could produce a critical adverse health effect and impact patients receiving the device.

    If a toxicological risk is equivocal, toxicologists base the next steps on understanding the toxicological risk. The qualifications and support of an experienced toxicologist are pivotal in determining acceptability of a toxicological risk and the overall biological risk of a final finished medical device.

    Since the industry expects the ISO 10993-17 revision to be released in 2022, expert toxicological risk assessors can help to prepare for the new requirements in future regulatory submissions.
     
    Putting It to Practice
    While the industry patiently awaits final publication of ISO 10993-17, many organizations are still implementing the changes engendered by ISO 10993-18:2020. These efforts can directly benefit toxicologists in anticipation of new guidance by establishing a solid foundational dataset of the chemicals to be assessed.
     
    References
    1 International Organization for Standardization. ISO 10993-1:2018. https://www.iso.org/standard/68936.html. Published August 2020. 
    2 International Organization for Standardization. ISO 10993-17:2002. https://www.iso.org/obp/ui/#iso:std:iso:10993:-17:ed-1:v1:en. Published 2002.
    3 International Organization for Standardization. ISO 10993-18:2020.  https://www.iso.org/standard/64750.html. Published January 2020
     
    Dr. Sherry Parker has more than 20 years of toxicology and medical device experience, and is an expert in biological evaluation of medical devices and combination products. She received her Ph.D. in Molecular and Cellular Pharmacology from the University of Miami. In her current position as WuXi AppTec’s Senior Director of Regulatory Toxicology, Dr. Parker provides manufacturers with guidance on global regulatory and technical requirements and testing program design. In May 2019, Dr. Parker was appointed to a three-year term as co-chair of the Biological Evaluation (AAMI/BE) Committee, the U.S. mirror committee for ISO 10993. In addition, she is currently an internationally recognized ISO expert and a U.S. Delegate for TC 194, the technical committee for ISO 10993, and is a past president of the Medical Device and Combination Products Specialty Section of the Society of Toxicology.
      Loading, Please Wait..

      Trending
      • Cardiosense Begins SEISMIC-HF I Heart Failure Trial
      • Danaher Names New Environmental And Applied Solutions Company Veralto
      • Exo Introduces The Exo Iris To Market
      • A New Approach To Post-Market Surveillance
      • Varian Buys Aspekt Solutions To Bolster Advanced Oncology Biz
      Breaking News
      • ISO 13485 Certification Awarded to Inspira Technologies
      • ZOLL Expands Temperature Management Portfolio to Include IQool System
      • Steven Goetz Joins Motif Neurotech as Chief Technology Officer
      • ZAP Surgical Wins Two More IP Battles with Elekta
      • 3D Systems Partners with Klarity to Expand Distribution of VSP Bolus Solution
      View Breaking News >
      CURRENT ISSUE

      October 2023

      • MPO's 2023 Medtech Supply Chain Survey
      • Exceeding Medical Device Extrusion Expectations
      • Medical Device Micromolders Discuss the 'Minor Details'
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      PLT Health Solutions Granted Claims for Botanical Ingredient in Canada
      CRN Files Petition with FTC For Clarity on Health Products Compliance Guidance
      Vitafoods Europe Relocates to Barcelona Starting 2025
      Coatings World

      Latest Breaking News From Coatings World

      Hugh Grant to Retire from PPG Board of Directors
      BASF Recognizes Hard Work with Five Prestigious Awards at SEMA
      Arkema Will Decarbonize Acrylics Production at its Carling, France Site
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Steven Goetz Joins Motif Neurotech as Chief Technology Officer
      ZAP Surgical Wins Two More IP Battles with Elekta
      3D Systems Partners with Klarity to Expand Distribution of VSP Bolus Solution
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Sartorius, SPARTA Biodiscovery Partner on Nanoparticle Analysis Platform
      Ono, Admid Partner on Novel Antibody Drugs in Oncology
      Theradaptive Awarded DOD Clinical Trial Award of up to $7.4M
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Taramar Unveils Skincare Solution Powered by Kelp
      NYX Professional Makeup Partners with the New York Liberty
      BASF and StitchCrew Introduce Educational Bootcamp for Indigenous Beauty Brands
      Happi

      Latest Breaking News From Happi

      Black Girl Ventures Foundation, Rare Beauty Brands and JCPenney Reveal 2023 National Competition Finalists
      Catch Partners with Rare Beauty, Introduces First Mobile App
      Haircolor Company oVertone and Franzia Wines Create Limited Edition Hair Conditioners
      Ink World

      Latest Breaking News From Ink World

      Arkema Will Decarbonize Acrylics Production at Carling, France Site
      Micro Powders Showcases New Natural, PTFE Alternative Additives at 2023 WCS
      Roland DG Direct-To-Film Printer Ink, Powder Receive ECO PASSPORT Certification
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Label Summit Latin America returns to Colombia
      INX brings inkjet and sustainable packaging to PRINTING United Expo
      Schreiner MediPharm introduces Freeze-Light-Protect syringe label
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Ed Thomas Receives INDA Lifetime Technical Service Award
      ExxonMobil Works with JL Goor to Help Drive Growth in Ireland and U.K. Healthcare Sector
      Lee C. Stewart Resigns from Glatfelter Board
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      FDA Clears 4WEB Medical's New Integrated Cervical Plate
      CTL Amedica Granted ECAT Approval from Defense Logistics Agency
      Intech Acquires Lenkbar LLC
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Emerson Ventures Invests in First Resonance
      Nearly Six in 10 Warehouse Leaders Plan to Deploy RFID by 2028: Zebra
      Wiliot to Show Enhanced Version of Wiliot Cloud, IoT Pixels, at MWC Las Vegas 2023

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login